GSK Entered into an Exclusive Licence Agreement and SCYNEXIS to Develop and Commercialise Brexafemme (ibrexafungerp) for Fungal Infection
Shots:
- SCYNEXIS to receive $90M up front, $503M in milestones incl. ~$70M in regulatory approval milestones, ~$115M in commercial milestones based on first commercial sale in invasive candidiasis (US/EU); ~$242.5M in sales milestones incl. $77.5M to be paid upon achievement of multiple thresholds up through $200M; $65M upon multiple thresholds b/w $300M & $500M & $50M at each threshold of $750M & $1B along with royalties across all indications
- SCYNEXIS will also receive ~$75.5M in success-based development milestones & holds rights to all other assets derived from enfumafungin along with leading the execution & costs of the ongoing clinical studies of ibrexafungerp. GSK gets the first rights to negotiate for future compounds developed by Scynexis
- GSK will get an exclusive license to develop, manufacture & commercialize ibrexafungerp & Brexafemme for all indications in all countries excl. greater China region & certain other countries already out-licensed by SCYNEXIS to third parties
Ref: gsk and scynexis | Image: gsk and scynexis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
